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CORRESPONDENCE
Biopsy vs. extensive resection for first 
recurrence of glioblastoma: is a prospective 
clinical trial warranted?
Christopher Dardis1*, Lynn Ashby1, William Shapiro1 and Nader Sanai2
Abstract 
Background: Glioblastoma is an aggressive and almost universally fatal tumor. The prognosis at the time of recur-
rence has generally been poor, with overall survival typically in the range of 4–40 weeks. The merits of surgical resec-
tion (vs. open biopsy, to confirm recurrence via histology) in addition to conventional adjuvant chemotherapy have 
been the subject of longstanding debate. We wondered whether it would possible to conduct a trial at our institution 
to settle this question definitively with Class I evidence.
Results: Initially, we had hoped to conduct a randomized, unblinded prospective clinical trial. However on closer 
inspection it appeared that such an undertaking would pose significant practical challenges. Thus we present our 
protocol in draft form. In keeping with recommended outcomes for these tumors, the primary endpoint would be 
median progression free survival. Secondary end points would be: median overall survival (mOS, from time of recur-
rence) and change in Karnofsky Performance Status over time. Patients would be eligible at the time of first recur-
rence if they had received conventional treatment until that point and at least 1 month had elapsed since the time of 
radiation. All patients would be considered potentially eligible for enrollment (unless the decision regarding resection 
was already clear-cut in view of other factors). Using Cox’s proportional hazards model, we estimate that at least 456 
patients would be necessary to demonstrate an increase in the hazard ratio to 1.3 for those undergoing biopsy alone. 
This magnitude of benefit is estimated based on a review of retrospective studies.
Discussion: If restricted to our Institution alone, which sees approximately 100–150 new cases of glioblastoma each 
year, a trial of this nature would be likely to take around 10 years. Furthermore, there may be significant reluctance on 
the part of patients and physicians to participate. There is also the opportunity cost of excluding patients from other 
trials to consider. We recognize that the estimate of the magnitude of effect may be conservative. As things stand, we 
feel that multi-institutional collaboration would almost certainly be required for an undertaking of this kind.
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Background
Glioblastoma (GB), meaning World Health Organiza-
tion Grade IV astrocytoma, is the most common pri-
mary brain tumor in adults [1]. These tumors are almost 
universally fatal. Its annual incidence is estimated to be 
3.2/100,000 in the United States [2]. Standard therapy 
for newly diagnosed patients with GB involves maximal 
surgical resection, followed by radiotherapy (RT, typi-
cally 60 Gray, given in 30 fractions) with concomitant 
and adjuvant temozolomide (TMZ) for at least 6 months. 
The addition of TMZ to RT has increased median over-
all survival (mOS) from 12.1 months to 14.6 months, and 
2-year survival from 10 to 26 % [3].
Recurrence of GB is almost inevitable. A meta-analysis 
of 8 Phase II studies involving 225 patients with recur-
rent GB showed a mOS after disease recurrence of just 
25 weeks and a progression-free survival rate at 6 months 
(PFS-6) of only 15 % [4].
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Accurately diagnosing recurrence remains a clini-
cal challenge. The standard adjuvant treatments of 
RT and TMZ lead to pseudo-progression on follow-
up imaging in 20–30 % of patients imaged at 2 months 
[5]. In order to differentiate tumor recurrence from 
radiographic pseudo-progression, a surgical speci-
men for histological analysis remains the reference 
standard.
Role of surgery at recurrence
In a minority of cases surgery is essential in order to 
relieve mass effect caused by tumor growth. However, 
once recurrence of tumor has been confirmed, surgery 
often proceeds with the goal of removal of as much of the 
remaining tumor as possible. This is particularly likely to 
be the case when the diagnosis can be determined during 
surgery via frozen section.
There has been considerable debate about the merits 
of such a strategy. This is reflected, for example, in the 
Canadian recommendations for the treatment of recur-
rent or progressive GB, which state: “In the absence of 
level I evidence, the decision to re-operate should be 
made according to individual circumstances, in consulta-
tion with the multidisciplinary team and the patient” [6]. 
By contrast, the USA’s National Comprehensive Cancer 
Network guideline for recurrent (local) GB favors resec-
tion when possible [7].
Where facilities are available, a consensus has devel-
oped that resection is advisable if the patient is well 
enough and the tumor accessible. It has been proposed 
that approximately 25 % of patients are eligible for repeat 
resection at recurrence or progression [8].
Historically, the earliest published work on the ques-
tion, from 1967, favors surgical resection for recurrent 
glioma (including GB). The authors view is that surgery 
requires as radical a removal of tumor as is feasible [9]. 
With some refinements, this has remained the general 
consensus since.
Clearly, some form of treatment is generally advisable 
at recurrence. This was argued in 2003 when a strategy 
of aggressive treatment [surgery, RT and chemotherapy 
(CT)] compared favorably with no intervention (n = 90 
vs. n = 78). Regarding surgery, the authors state that: “the 
major criteria guiding this decision were location and 
tumor size (both influencing the chance of a macroscopic 
total resection), mass effect, and the impact of surgery on 
additional strategies” [10].
Other important retrospective series addressing the 
question appear in Table  1 [11–16]. This represents a 
spectrum of opinion. Some strongly favor re-operation 
[17–19]. Others have been more sanguine [20, 21].
The role of resection at recurrence of GB (includ-
ing second recurrence and beyond), has most forcefully 
been argued by Chaichana et  al. in 2013 in their cohort 
of 579 patients [22]. The authors conclude that: “patients 
who underwent an increasing number of resections had 
increased survival benefit regardless of age, functional 
status, and other factors”. They do acknowledge the caveat 
that their findings “may be limited by an inherent bias 
in patient selection, which may favor patients with more 
benign tumor biology”.
Nonetheless, the most comprehensive review on the 
question of resection to date (evaluating 11 studies) 
Table 1 Estimates of survival following recurrence of glio-
blastoma
Brackets indicate 95 % CI where available
n number of patients in study, Tx treatment, Sx surgery, RT radiotherapy, CT 
chemotherapy, mPFS median progression free survival (weeks), mOS median 
overall survival (weeks), KPS Karnofsky performance status, NA not available, 
LRCT locoregional CT (i.e. bleomycin + mitoxantrone via Ommaya reservoir), P II 
Phase II studies
N Tx mPFS mOS
Series involving resection ± additional adjuvant Tx at recurrence
 Quick [26] 29 GRT ± RT, CT NA 66.5
11 SRT ± RT, CT NA 37.4
 DeBonis [11] 17 Sx NA 26 (13–39)
19 No Tx NA 22 (13–30)
24 CT NA 35 (22–43)
16 Sx + CT ± RT NA 61 (43–78)
 Clarke [24] 758 CT (P II) 8.3 (8.0–9.6) 31.4 (25.3–35.9)
 Park [27] 34 Sx NA 4–46.8 varies by 
NRGS
 McGirt [20] 294 Sx (GTR) NA 51
 Mandl [14] 9 Sx (≥1) NA 13
11 Sx + SRS/CT NA 34
12 SRS/CT NA 28
 Hau [10] 90 Sx, RT, CT 13 (10–13) 33 (26–39)
78 No Tx 15 % at 12 mos 9 (4–15)
 Pinsker [13] 38 NA 18–21
 Guyotat [20] 18 Sx NA 22.6
36 No Sx NA 8.6
 Barker [21] 43 Sx (≥1) NA 42 (37–50)
130 No Sx NA 23 (20–29)
 Landy [11] 12 Sx ± RT, CT NA 8





35 Sx ± RT, CT NA 29
Series using adjuvant bevacizumab at recurrence
 Friedman 
[31]
85 Bev 18.5 (12.6–25.2) 40 (35.6–46.5)
 Kresyl [32] 48 Bev 16 (12–26) 31 (21–54)
Series using CT (not bevacizumab) at recurrence
 Lamborn 
[33]
437 CT (P II) 8 (8–9) 30 (27–33)
 Wong [4] 225 CT (P II) 9 (8–10) 25 (21–28)
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concluded that there is no established role for surgery in 
this setting [23]. The patient’s age and Karnofsky Perfor-
mance Status (KPS) were identified as important prog-
nostic predictors and, to a lesser extent, the size of the 
tumor.
The largest single retrospective study to address the 
question has been that of the North American Brain 
Tumor Consortium. The group looked at Phase II stud-
ies in recurrent GB (1998–2005, n = 511) and concluded 
that progression-free survival and overall survival are 
similar irrespective of surgery. [24] They suggest that 
surgery at recurrence “balances the scales, permitting 
patients who would otherwise do worse due to bulky 
tumor to do as well as patients who do not require 
surgery”.
Other recent reviews have tended to be more favora-
ble to resection. One from 2008 concluded that reop-
eration probably provides an average improvement of 
3–5  months in mOS. Amongst the conclusions are that 
the ‘ideal’ patient is “less than 50  years old (although 
older patients can benefit), has a KPS of greater than or 
equal to 60–70; [has a] tumor in a favorable location; 
[has a tumor where] a 98 % resection is possible; and [has 
been progression free for] more than 6 months since the 
initial diagnosis” [25].
Another, from 2014, with 40 patients, tended to favor 
surgery and concluded that patients in good clinical con-
dition should not have the option of second surgery with-
held [26].
Stereotactic radiosurgery (SRS), particularly Gamma 
Knife®, has also been proposed as a safe and effective 
alternative to a second resection in selected patients 
[27]. Similarly to our own proposal regarding resection, 
a review of studies to date (nine studies, n = 283 cases) 
addressing the value of radiosurgery in this setting also 
favors a randomized clinical trial (RCT) to address the 
question of selection bias [28].
Stratification
Scoring systems have been proposed to help individual-
ize decision making in these circumstances. The first of 
these, in 2010, the NIH Recurrent GB Scale (NRGS), is 
a 0–3 point scale which identified the following as inde-
pendent predictors of poor prognosis:
  • postoperative KPS score ≤80
  • tumor volume ≥50 cm3
  • involvement of ≥2 of 3 critical areas of cortex:
• Motor
•  Speech
• MCA (areas adjacent to the M1/M2 areas of the 
Middle Cerebral Artery)
This was derived from (n  =  34) and validated with 
(n = 109) a cohort of patients who all underwent surgery. 
The authors propose that those with ≤2 points “have sig-
nificantly longer expected postoperative survival periods, 
and [that] reoperation, if indicated, should be pursued” 
[29].
Another series from 2013 identified two important pre-
dictors of poor survival: [30]
  • KPS ≤70
  • enhancement of the ventricular wall
Again, this was derived from (n  =  55) and validated 
with (n =  96) patients undergoing surgery. The authors 
recommend that “for patients with a score of 2 [i.e. hav-
ing both risk factors], surgery is not recommended and 
conservative management may be better”.
Role of bevacizumab at recurrence
Regardless of the decision on whether to proceed with 
surgery, some form of additional CT at recurrence is gen-
erally agreed to be worthwhile where possible. Although 
no one agent has yet been endorsed by existing guide-
lines, all of them give prime consideration of bevaci-
zumab. Although no Phase III trial has been performed 
to validate this strategy, it has been approved by the Fed-
eral and Drug Administration (FDA) on the basis of who 
Phase II studies, both published in 2009. In that by Fried-
man et  al., those using bevacizumab alone had a PFS-6 
of 43 % and mOS of 40 weeks (95 % CI 35.6–46.5) [31]. 
That by Kresyl et  al. showed a PFS-6 of 57  % (95  % CI 
44–75) and mOS of 31 weeks (95 % CI 21–54) [32]. This 
was a favorable outcome with respect to historical con-
trols (those treated with temozolomide alone).
At least one trial undertaken since then has called into 
question the use of single-agent bevacizumab as adjuvant 
chemotherapy when GB progresses. However a consen-
sus has yet to emerge on whether dual-agent treatment 
should be implemented routinely in this setting. [33]
Results
Trial design
The protocol itself is available as a Additional file 1. The 
document was generated using LaTeX. Those wishing to 
adapt the protocol can also find a printout of the source 
code used to generate this as Additional file 2. The sec-
tions which follow refer to this draft protocol, which is 
presented as a single-institution study. An overview of 
the trial design is presented in Fig. 1.
Based on the retrospective data in Table 1, we believe that 
extensive resection is likely to improve mPFS. Owing to the 
lack of prospective data to guide the decision on the extent of 
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resection at recurrence, we designed an RCT (unblinded) to 
settle the question more definitively. The goal is to generate 
Class I evidence to guide clinicians in this difficult decision.
Endpoints
The primary endpoint is mPFS after first recurrence 
of GB [34]. Secondary endpoints are: PFS-6 after first 
recurrence of GB, mOS and change in KPS over time. 
Progression is to be determined by clinical judgment, 
supplemented by imaging. As KPS is an ordinal scale, we 
propose to compare KPS scores at 3 and 6 months using 
non-parametric tests.
If there was robust evidence in favor of resection, we 
also plan to perform regression to attempt to control 
for additional variables which are known to be associ-
ated with outcome. These include the NRGS as above 
as well as age, KPS and proportion of tumor resected. 
This latter would be calculated from the volume on 
enhancement on pre- and post- operative MRIs. How-
ever, as the trial sample size is based on the effect size 
of the intervention on the primary endpoint and as 
the trial stops at interim analysis if this endpoint is 
reached, it is likely to be under-powered to control ade-
quately for these confounders. As the extent of resec-
tion cannot be determined accurately prior to surgery, 
there is no easy way to control for this through strati-
fied randomization.
Initial treatment
Initial treatment is according to our current standard of 
care. Patients with suspicion of GB based on clinical and 
radiological characteristics would undergo surgery; if the 
frozen section confirmed the diagnosis, an attempt at 
maximal resection would be pursued.
Enroll:
First recurrence of GBM
Age ≥ 18
KPS ≥ 70





0 vs. 1 vs. 2 vs. 3
• KPS ≤ 80
• tumor volume ≥ 50cm−3
• ≥ 2 cortical areas involved:
◦ Motor
◦ Speech
◦ MCA (affected areas adjacent to






Fig. 1 Trial design overview
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Following this, intensity-modulated radiation treat-
ment (IMRT) is given (typically 55–60 Gy) with con-
current and adjuvant TMZ as per the original Stupp 
protocol [35]. This starts within 8  weeks of the pri-
mary resection (typically 3  weeks). Adjuvant TMZ 
is administered at cycles 5  days/month for at least 
6  months. Although the Stupp protocol contin-
ued adjuvant treatment for 6  months, it has since 
become accepted practice to continue this for at least 
12  months. Beyond 12  months, the use of TMZ is 
individualized. We plan to continue treatment beyond 
this as tolerated, based on a retrospective series show-
ing signs of benefit [36].
We accept patients whose initial care had taken place 
elsewhere, provided their care has been similar to that 
outlined above, as judged on an intention-to-treat basis.
Surgery at recurrence
Patients are considered eligible for surgery at recurrence 
based on the opinion of their treating Neurosurgeon. All 
adult patients with a KPS of ≥70 are considered poten-
tially eligible at the time of recurrence, unless there are 
factors present which would ‘tip the scales’ entirely in 
one direction; for example major systemic co-morbidity, 
tumor in an unresectable location (bi-thalamic, dif-
fuse pontine) or mass effect from the tumor putting the 
patient at immediate risk of complications such as her-
niation or blockage of a major artery.
Patients randomized to resection undergo routine, 
image-guided cyto-reduction targeting the contrast-
enhancing portion of the lesion on T1-weighted con-
trast-enhanced magnetic resonance imaging (MRI). 
Intraoperative adjuncts, including, and not limited to, 
5-aminolevulinic acid, intraoperative MRI and intraoper-
ative monitoring using electrodes, are included as needed 
per the treating Neurosurgeon. Carmustine (Gliadel®) 
wafers are not implanted.
Patients randomized to open biopsy undergo an image-
guided biopsy using a minimal craniotomy and open 
microsurgical techniques (This differs from a stereotactic 
needle biopsy. We prefer an open biopsy due to its supe-
rior diagnostic accuracy [37]).
Further chemotherapy
Treatment is with bevacizumab, 10 mg/kg every 2 weeks. 
The first dose is given 2–4 weeks after the date of surgery 
or biopsy. This is continued indefinitely (as tolerated) until 
time of progression. Full details of reporting and manage-
ment of adverse events are included in the protocol.
Monitoring
Patients follow up with their Neuro-Oncologist at 
monthly intervals. MRIs are repeated every 2 months, or 
sooner if new symptoms or signs occur which are con-
cerning for disease progression. KPS is assessed at each 
of these visits.
Treatment at time of progression
At time of subsequent progression, the patient is re-eval-
uated at our weekly Multidisciplinary Central Nervous 
System Tumor Conference. Decisions are individualized 
but include the options of further surgery, further IMRT, 
SRS, a change in chemotherapy, treatment with electrical 
fields (Optune®) and Palliative Care.
Sample size considerations
Following a review of cases seen at our Institution from 
2009 to 2012, we estimate 50–70 cases/year of first recur-
rence of GB. We estimate that 60  % will be eligible for 
entry to and agreeable to participation in the study. We 
realize this figure is higher than the 25 % previously cited 
but felt this more realistically represents current practice 
in our setting [8].
Following standard statistical methods, we assume that 
the survival distributions for both groups will be exponen-
tial [38]. The hazard radio (HR) is thus the reciprocal of the 
ratio of median survival times. For example if the mPFS 
was 17 weeks in those treated with biopsy and 34 weeks 
with surgery, the HR is 1/(17/34) = 2. Based on Table 1 as 
well as our own experience, we believe that the mPFS in 
those treated with surgery will be closer to 23 weeks, giv-
ing a HR of approximately 1.3 (or 1/1.3 = 77 % for patients 
undergoing resection vs. biopsy alone).
The numbers required for various effect sizes and val-
ues for the power of the test are illustrated in Table  2. 
These are derived, as is typical, using the method of Sch-
oenfeld, where all subjects are followed until the event of 
interest occurs (progression or death). [39] Significance 
is two-sided, meaning that those undergoing biopsy only 
have 1.4× the risk of progression in the period of time 
under consideration. Thus with a HR of 1.3 and a power 
of 80  %, the trial would require 456 participants and 
would need to run for 11  years (40 entrants/year). This 
assumes that all patients proceed with the intervention 
to which they are randomized and that all are followed 
until death or further progression of disease. For GB it 
Table 2 Sample size necessary to  demonstrate a signifi-
cant difference in hazard ratio (HR)
Assumes two-sided significance (alpha) of 5 %
Power (%) HR
1.2 1.3 2.0
70 742 359 51
80 945 456 65
90 1264 611 87.5
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appears a reasonable assumption that that all will pro-
gress again at some point.
Costing
While precise costing is beyond the scope of the pre-
sent paper, these are likely to be small relative to onco-
logic trials in general. In particular, both resection and 
open biopsy are considered ‘standard of care’, as are all 
of the specified treatments. Thus the only costs would 
be administrative: help from a Nurse trained in clinical 
research would be valuable in helping to explain the con-
sent form to patients and their families; help would also 
be valuable for data entry and adverse event reporting, 
given the constraints on the treating physicians’ time. 
Additional administrative costs may arise from a data-
monitoring committee and Institutional Review Board. 
Bearing all of this in mind, we feel that a trial such as this 
could be run for less than $60,000 per year.
Discussion
Similar trials
Ours in not a novel design. We are aware of another 
a similar RCT designed to compare the use of bevaci-
zumab with or without surgery at time of progression of 
GB [40]. This study was withdrawn from ‘clinicaltrials.
gov’ before patient enrollment began. The sample size 
is substantially smaller, with 42 participants allocated to 
each arm; thus the estimated effect size is expected to be 
much larger; for a sample size of 84, the HR would need 
to be approximately 1.75 to demonstrate a difference via 
the log-rank test (assuming complete follow up). The pri-
marily endpoint, mOS differs from ours. Also, patients 
are not required to have histologically confirmed recur-
rence at the time of progression, as in our protocol.
Estimates of effect and sample size
We acknowledge that our estimate of the HR may be 
overly cautious. Likewise, our service is growing over 
time so that our estimate of the number of eligible 
patients each year may be too small. As explained below, 
we feel it is worth erring on the side of caution in the 
design of a trial such as this.
The difficulties caused by insufficient sample size in 
surgical trials have been highlighted in diverse fields; 
for example, reviews of the topic have been undertaken 
in Orthopedic and Cardiothoracic Surgery [41, 42]. 
The authors of the latter review conclude that “for most 
study questions in clinical surgery, comparative analy-
sis of large case series and databases will provide more 
robust evidence”. We will return to this suggestion in the 
conclusions.
Estimating the magnitude of effect size in a trial such as 
this is made more challenging owing to the heterogeneity 
of reported outcomes in the existing literature. Over 
time, a consensus has emerged that mPFS is the likely 
to be the most valuable measure of efficacy in recurrent 
GB. The older studies have tended to favor mOS as an 
endpoint. However this is becoming complicated by an 
increasing range of therapeutic options when signs of 
further progression develop. Furthermore, interventions 
tend to become increasingly individualized as the disease 
progresses. These later interventions would be challeng-
ing to standardize and may obscure the earlier effects of 
initial treatment on outcome.
While we settled on a HR of 1.3, which would lead to 
a sample size of at least 456, a more conservative design 
would allow for a sample size sufficient to demonstrate a 
difference between groups with a HR of 1.2. This would 
more than double the sample size, to 945, which is large 
by the standards of clinical trials in this field. The rela-
tion of sample size to HR is not a linear and as the HR 
approaches 1 the sample size increases dramatically. This 
is illustrated in Fig. 2. This figure of 456 is something of 
a ‘tipping point’ in that larger sizes appear beyond the 
scope of most centers acting individually. A trial such as 
this would, ideally, only need to be performed once. This 
more conservative estimate would mitigate against the 
trial being under-powered and inconclusive. If an annual 
review of results to date were to be performed accord-
ing to the traditional methods of O’Brien and Fleming, it 
would still have the potential to end long before the tar-
get sample size had accrued [43].
While such a small improvement (HR of 1.2) may seem 
overly pessimistic, it would at least avoid the difficulty of 
interpreting a negative result with a smaller number of 
patients enrolled [44]. The corollary is that there is little 
to lose by over-powering this type of trial; indeed once the 
required organizational structure was in place, it could 
readily be adapted to similar questions in the field.
A multi‑institutional endeavor?
Such an undertaking is likely to prove difficult for any 
single center and thus multi-institutional collaboration, 
possibly international, is likely to be necessary. Such an 
approach has already proved feasible in other trials of 
adjuvant treatments for GB, with target sample sizes of 
over 950 now achievable [45]. Given that there are an 
estimated 18,000 patients newly diagnosed with GB each 
year in the USA alone, then with sufficient co-ordination 
even a sample size such as this could accrue rapidly.
In a multi-institutional trial of surgery there would 
be a great need to ensure standardization of tech-
niques. The variability due to different treatment cent-
ers can be accounted for using ‘clustered’ analysis, 
or multilevel/’mixed-effects’ models, although such 
approaches may further inflate the required sample size. 
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There may also be resistance from local Neurosurgeons 
to the imposition of standardization and to randomiza-
tion taking place remotely.
Treatment preferences: patient and physician
Bias, in the form of patient preference, appears to be the 
biggest obstacle to the design of randomized trials in 
surgery. It is likely that there exists an inherent, intuitive 
bias in favor of surgery in most patients. This appears to 
be particularly true for the evaluation of treatments for 
malignancy, in the comparison or surgical with non-
surgical approaches and where survival is a primary end-
point [46]. All of these factors are present to some degree 
in our draft protocol.
Bias may also exist for the Neurosurgeon. In order to 
randomize the decision to proceed with surgery at the 
time of recurrence, true clinical equipoise is required. 
We believe this is unlikely to be the case in the major-
ity of our patients, when considered from the perspective 
of the treating Neurosurgeon. By proposing randomiza-
tion, the treating clinicians may feel that their judgment 
and experience are being undermined. In addition, insti-
tutions seeing patients with this condition are likely to 
have established preferences for attempt at resection vs. 
biopsy. Difficulties such as this have been identified as a 
barrier to recruitment in other clinical trials and feelings 
of lack of equipoise appear to be greater among surgeons 
than other physicians [47, 48].
Alternatives to the RCT
To overcome these difficulties, a number of alternatives 
to the traditional RCT have been proposed [49]. One 
possibility is ‘pre-randomization’, whereby randomiza-
tion occurs prior to informed consent i.e. the patient is 
presented with the recommended treatment without 
consideration of an alternative. While attractive theoreti-
cally, we suggest that in the modern regulatory context 
this is unlikely to pass muster with most Institutional 
Review Boards.
Another is the ‘patient preference’ design; this allows 
the treating patient and surgeon to decide on appropriate 
treatment; only where lack of preference exists is rand-
omization performed. This mirrors the ‘real-world’ sce-
nario most closely. One difficulty here is that the arms 
are likely to become weighted towards one treatment, 
making statistical conclusions fraught. Furthermore, 
this design is likely to have an imbalance in confounding 
variables such that the results would be less likely to gain 
acceptance.
In any of these designs, including the RCT, is has been 
suggested that the traditional p  <  0.05 criteria for sig-
nificance be relaxed to take account of the difficulties 
inherent in surgical trials. This appears justified, in that 
smaller numbers of subjects will tend to increase the p 
value (unless the null hypothesis is true). However, no 
clear consensus exists as to what alternative level of sig-
nificance to use.
The simplest approach to a question such as this is a 
historical-control trial (HCT). This has been discouraged 
on the grounds that HCTs tend to have more positive 
outcomes that those following a RCT design. The most 
through review on the subject, involving six common 
medical conditions for which 50 RCTs and 56 HCTs were 
available, showed that the proposed treatment improved 
outcomes in 80 % of the HCTs and only 20 % of the RCTs. 
This difference was attributed to differences in the con-
trol group and remained after HCTs were adjusted for 
confounding prognostic factors [50]. The same authors 
Fig. 2 Graph showing the relationship between required hazard ratio and sample size. Sample size is plotted on a log scale (base 10). Significance 
(alpha, two-sided) = 0.05. Power = 80 %
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give a sensitivity and specificity for these methods, shown 
in Table  3 [51]. Admittedly, only one of these interven-
tions was surgical (surgery for esophageal varices).
Effect on other trials
There would be an ‘opportunity-cost’ of participating 
in our protocol. Patients would lose the opportunity to 
participate in other studies. There are typically a large 
number of such trials enrolling for the treatment of first 
recurrence of GB, the majority of which involve CT (at 
the time of writing there were approximately 20 in the cat-
egory of immunotherapy alone) [52]. Many of these will 
have stronger expectations of benefit than the advantages 
we would attribute to second resection (vs. open biopsy). 
This is particularly the case in that the disease is likely to 
have become more multifocal and diffuse at the time of 
recurrence, even if this pattern is not obvious on conven-
tional MRI. Thus, more systemically-targeted treatments 
are likely to be stronger candidates for consideration at 
the time of disease progression.
Conclusions
Even with a modest improvement in outcome, we feel 
that such a trial would be worthwhile. However, while 
attractive on theoretical grounds, a trial such as this is 
faced with a number of barriers to practical implemen-
tation. The greatest amongst these are the sample size 
required and the probable duration of the trial. These are 
far from insurmountable.
For now, it is likely that we will have to settle for the 
technique of use of historical controls. Despite the short-
comings of this approach, we hold to the maxim that 
‘the good is not the enemy of the best’. In due course, the 
cumulative evidence from reported cases should establish 
a consensus. With greater standardization of stratifying 
predictors and of outcomes, and with sufficient pooling 
of data, this should become increasingly tractable.
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